Phase I/II Trial of the Addition of PD 0332991 to Cetuximab in Patients With Incurable Squamous Cell Carcinoma of the Head and Neck (SCCHN)

Trial Profile

Phase I/II Trial of the Addition of PD 0332991 to Cetuximab in Patients With Incurable Squamous Cell Carcinoma of the Head and Neck (SCCHN)

Recruiting
Phase of Trial: Phase I/II

Latest Information Update: 18 Apr 2018

At a glance

  • Drugs Cetuximab (Primary) ; Palbociclib (Primary)
  • Indications Head and neck cancer
  • Focus Adverse reactions; Therapeutic Use
  • Most Recent Events

    • 12 Apr 2018 Planned primary completion date changed from 1 Aug 2017 to 31 Aug 2019.
    • 12 Apr 2018 Planned number of patients changed from 72 to 93.
    • 12 Apr 2018 Planned End Date changed from 31 Aug 2022 to 31 Aug 2023.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top